PI3K/AKT/mTOR pathway inhibitors: the ideal combination partners for breast cancer therapies?
出版年份 2014 全文链接
标题
PI3K/AKT/mTOR pathway inhibitors: the ideal combination partners for breast cancer therapies?
作者
关键词
-
出版物
Expert Review of Anticancer Therapy
Volume 15, Issue 1, Pages 51-68
出版商
Informa UK Limited
发表日期
2014-10-11
DOI
10.1586/14737140.2015.961429
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765 (SAR245409), a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced malignancies.
- (2017) I. Brana et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with erlotinib in patients (pts) with advanced solid tumors.
- (2017) C. Moldovan et al. JOURNAL OF CLINICAL ONCOLOGY
- First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors.
- (2017) H. Burris et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I dose-escalation study of XL147 (SAR245408), a PI3K inhibitor administered orally to patients (pts) with advanced malignancies.
- (2017) G. Edelman et al. JOURNAL OF CLINICAL ONCOLOGY
- Use of biomarkers and imaging to evaluate the treatment effect of AUY922, an HSP90 inhibitor, in patients with HER2+ or ER+ metastatic breast cancer.
- (2017) C. P. Schroder et al. JOURNAL OF CLINICAL ONCOLOGY
- Final results of a translational phase l study assessing a QOD schedule of the potent AKT inhibitor MK-2206 incorporating predictive, pharmacodynamic (PD), and functional imaging biomarkers.
- (2017) T. A. Yap et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of the oral AKT inhibitor GSK2141795 (GSK795) in a phase I first-in-human study.
- (2017) H. A. Burris et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I study of the AKT inhibitor (MK-2206) with concurrent trastuzumab and lapatinib in patients with HER2-positive solid tumors.
- (2017) H. S. Han et al. JOURNAL OF CLINICAL ONCOLOGY
- Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health
- (2015) William H. Chappell et al. Oncotarget
- Abstract 1038: Inhibition of mTOR enhances the activity of HSP90 inhibitors in part through cessation of heat shock protein synthesis.
- (2014) Suqin He et al. CANCER RESEARCH
- Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors
- (2014) Jordi Rodon et al. INVESTIGATIONAL NEW DRUGS
- Tracking and Evaluating Molecular Tumor Markers With Cancer Registry Data: HER2 and Breast Cancer
- (2014) William F. Anderson et al. JNCI-Journal of the National Cancer Institute
- Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial
- (2014) Fabrice André et al. LANCET ONCOLOGY
- Characterization of the Novel and Specific PI3K Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials
- (2014) C. Fritsch et al. MOLECULAR CANCER THERAPEUTICS
- A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy
- (2013) Sara A. Hurvitz et al. BREAST CANCER RESEARCH AND TREATMENT
- Breast cancer statistics, 2013
- (2013) Carol DeSantis et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Conditional Loss of ErbB3 Delays Mammary Gland Hyperplasia Induced by Mutant PIK3CA without Affecting Mammary Tumor Latency, Gene Expression, or Signaling
- (2013) Christian D. Young et al. CANCER RESEARCH
- Combination of Antibody That Inhibits Ligand-Independent HER3 Dimerization and a p110 Inhibitor Potently Blocks PI3K Signaling and Growth of HER2+ Breast Cancers
- (2013) J. T. Garrett et al. CANCER RESEARCH
- Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors
- (2013) G. I. Shapiro et al. CLINICAL CANCER RESEARCH
- Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor Models
- (2013) J. Lin et al. CLINICAL CANCER RESEARCH
- Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma
- (2013) J. Rader et al. CLINICAL CANCER RESEARCH
- Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer
- (2013) F. Andre et al. CLINICAL CANCER RESEARCH
- The PI3K/Akt signaling pathway regulates the expression of Hsp70, which critically contributes to Hsp90-chaperone function and tumor cell survival in multiple myeloma
- (2013) M. Chatterjee et al. HAEMATOLOGICA
- Enhanced PI3K p110 Signaling Confers Acquired Lapatinib Resistance That Can Be Effectively Reversed by a p110 -Selective PI3K Inhibitor
- (2013) S. W. Brady et al. MOLECULAR CANCER THERAPEUTICS
- Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib‡
- (2012) S. George et al. ANNALS OF ONCOLOGY
- Pharmacologic Inhibition of mTOR Improves Lapatinib Sensitivity in HER2-Overexpressing Breast Cancer Cells with Primary Trastuzumab Resistance
- (2012) Sylvia S. Gayle et al. Anti-Cancer Agents in Medicinal Chemistry
- Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer
- (2012) Tobias J. Grob et al. BREAST CANCER RESEARCH AND TREATMENT
- Co-targeting of the PI3K pathway improves the response of BRCA1 deficient breast cancer cells to PARP1 inhibition
- (2012) Siker Kimbung et al. CANCER LETTERS
- Abstract 3749: Single agent activity of PIK3CA inhibitor BYL719 in a broad cancer cell line panel
- (2012) Alan Huang et al. CANCER RESEARCH
- Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy
- (2012) C. Garcia-Garcia et al. CLINICAL CANCER RESEARCH
- PI3K Pathway Inhibitors: Better Not Left Alone
- (2012) Ben Markman et al. CURRENT PHARMACEUTICAL DESIGN
- Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study
- (2012) Thomas Bachelot et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus As First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
- (2012) Antonio C. Wolff et al. JOURNAL OF CLINICAL ONCOLOGY
- Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background
- (2012) B. R. Davies et al. MOLECULAR CANCER THERAPEUTICS
- Mammalian Target of Rapamycin as a Rational Therapeutic Target for Breast Cancer Treatment
- (2012) Patricia Mucci LoRusso ONCOLOGY
- Multiorgan Metastasis of Human HER-2+ Breast Cancer in Rag2−/−;Il2rg−/− Mice and Treatment with PI3K Inhibitor
- (2012) Patrizia Nanni et al. PLoS One
- PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
- (2012) Yasir H. Ibrahim et al. Cancer Discovery
- Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer
- (2012) Ashish Juvekar et al. Cancer Discovery
- Abstract S1-4: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of AMG 479 With Exemestane (E) or Fulvestrant (F) in Postmenopausal Women With Hormone-Receptor Positive (HR+) Metastatic (M) or Locally Advanced (LA) Breast Cancer (BC):
- (2011) PA Kaufman et al. CANCER RESEARCH
- Phase I/II Study of Trastuzumab in Combination With Everolimus (RAD001) in Patients With HER2-Overexpressing Metastatic Breast Cancer Who Progressed on Trastuzumab-Based Therapy
- (2011) Phuong K. Morrow et al. JOURNAL OF CLINICAL ONCOLOGY
- Phosphatidylinositol 3-Kinase and Antiestrogen Resistance in Breast Cancer
- (2011) Todd W. Miller et al. JOURNAL OF CLINICAL ONCOLOGY
- Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
- (2011) Daniel D. Von Hoff et al. JOURNAL OF CLINICAL ONCOLOGY
- GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway
- (2011) J. J. Wallin et al. MOLECULAR CANCER THERAPEUTICS
- Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor
- (2011) S.-M. Maira et al. MOLECULAR CANCER THERAPEUTICS
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment of metastatic breast cancer: second line and beyond
- (2010) H. Roche et al. ANNALS OF ONCOLOGY
- Triple-Negative Breast Cancer
- (2010) Steven J. Isakoff CANCER JOURNAL
- Phase I Study of Everolimus Plus Weekly Paclitaxel and Trastuzumab in Patients With Metastatic Breast Cancer Pretreated With Trastuzumab
- (2010) Fabrice Andre et al. JOURNAL OF CLINICAL ONCOLOGY
- Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets
- (2010) N Turner et al. ONCOGENE
- PARP-1 inhibition-induced activation of PI-3-kinase-Akt pathway promotes resistance to taxol
- (2009) Arpad Szanto et al. BIOCHEMICAL PHARMACOLOGY
- Basal Subtype and MAPK/ERK Kinase (MEK)-Phosphoinositide 3-Kinase Feedback Signaling Determine Susceptibility of Breast Cancer Cells to MEK Inhibition
- (2009) O. K. Mirzoeva et al. CANCER RESEARCH
- Biology, Metastatic Patterns, and Treatment of Patients with Triple-Negative Breast Cancer
- (2009) Carey K. Anders et al. Clinical Breast Cancer
- Phosphoinositide 3-Kinase Mutations in Breast Cancer: A "Good" Activating Mutation?
- (2009) S. Di Cosimo et al. CLINICAL CANCER RESEARCH
- Targeting the phosphoinositide 3-kinase pathway in cancer
- (2009) Pixu Liu et al. NATURE REVIEWS DRUG DISCOVERY
- Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells
- (2009) Saskia M. Brachmann et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235
- (2008) P. J.A. Eichhorn et al. CANCER RESEARCH
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now